Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (41-50 of 174) with videos related to

Pageof 18
Sort By:
Nature Reviews. Clinical Oncology|August 23, 2017
A further strategy to combat the high price of anticancer drugsVinay Prasad, Kevin De Jesús, Sham Mailankody
Nature Reviews. Clinical Oncology|February 1, 2023
GPRC5D as a novel immunotherapeutic target in multiple myelomaKarthik Nath, Bruno A Costa, Sham Mailankody
The New England Journal of Medicine|December 14, 2022
GPRC5D-Targeted CAR T Cells for Myeloma. ReplySham Mailankody, Renier J Brentjens, Eric L Smith
Clinical Advances in Hematology & Oncology : H&O|February 6, 2015
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategiesDickran Kazandjian, Sham Mailankody, Neha Korde, et al.
Blood Cancer Journal|December 15, 2017
Clinically meaningful benefit: real world use compared against the American and European guidelinesJessica J Dreicer, Sham Mailankody, Farhad Fakhrejahani, et al.
JAMA Oncology|October 7, 2016
The Rising Price of Cancer Drugs-A New Old Problem?Vinay Prasad, Ruibin Wang, Salma H Afifi, et al.
CMAJ Open|January 19, 2018
Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutesMichael J Hayes, Victoria Kaestner, Sham Mailankody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
Dilemmas in treating smoldering multiple myelomaInhye E Ahn, Sham Mailankody, Neha Korde, et al.
The New England Journal of Medicine|October 11, 2023
Genetic Basis of Relapse after GPRC5D-Targeted CAR T CellsXiaoli Mi, Alex Penson, Omar Abdel-Wahab, et al.
Frontiers in Oncology|August 23, 2024
Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myelomaIssam S Hamadeh, Reed Friend, Sham Mailankody, et al.
Pageof 18

Showing results (41-50 of 174) with videos related to

Sort By:
Pageof 18
Nature Reviews. Clinical Oncology|August 23, 2017
A further strategy to combat the high price of anticancer drugsVinay Prasad, Kevin De Jesús, Sham Mailankody
Nature Reviews. Clinical Oncology|February 1, 2023
GPRC5D as a novel immunotherapeutic target in multiple myelomaKarthik Nath, Bruno A Costa, Sham Mailankody
The New England Journal of Medicine|December 14, 2022
GPRC5D-Targeted CAR T Cells for Myeloma. ReplySham Mailankody, Renier J Brentjens, Eric L Smith
Clinical Advances in Hematology & Oncology : H&O|February 6, 2015
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategiesDickran Kazandjian, Sham Mailankody, Neha Korde, et al.
Blood Cancer Journal|December 15, 2017
Clinically meaningful benefit: real world use compared against the American and European guidelinesJessica J Dreicer, Sham Mailankody, Farhad Fakhrejahani, et al.
JAMA Oncology|October 7, 2016
The Rising Price of Cancer Drugs-A New Old Problem?Vinay Prasad, Ruibin Wang, Salma H Afifi, et al.
CMAJ Open|January 19, 2018
Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutesMichael J Hayes, Victoria Kaestner, Sham Mailankody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
Dilemmas in treating smoldering multiple myelomaInhye E Ahn, Sham Mailankody, Neha Korde, et al.
The New England Journal of Medicine|October 11, 2023
Genetic Basis of Relapse after GPRC5D-Targeted CAR T CellsXiaoli Mi, Alex Penson, Omar Abdel-Wahab, et al.
Frontiers in Oncology|August 23, 2024
Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myelomaIssam S Hamadeh, Reed Friend, Sham Mailankody, et al.
Pageof 18